PubMed 11. Ereshefsky L, Jhee S, Phillips D, et al. Assessment of the maximum tolerated dose (MTD) of lurasidone in patients with schizophrenia [poster]. 48th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 6–10; Hollywood (FL) 12.
Sramek JJ, Block GA, Reines MK5108 supplier SA, et al. A multiple-dose safety trial of epastigmine in Alzheimer’s disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1995; 56 (5): 319–26.CrossRefPubMed 13. Lefevre G, Sedek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther 2008; 83 (1): 106–14.CrossRef 14. Gobburu JV, Tammara V, Lesko L, et al. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer’s disease. J Clin Pharmacol 2001; 41 (10): 1082–90.CrossRefPubMed 15. Cutler NR, Jhee SS, Cyrus P, et al. Safety and tolerability of metrifonate: results of a maximum
tolerated dose study. Life Sci 1996; 62 (16): 1433–41.CrossRef 16. Sramek JJ, Eldon MA, Posvar EL, et al. Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharm Bull 1998; 34 (1): 93–8. 17. Cutler NR, Murphy MF, Nash RJ, et al. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Endonuclease Alzheimer’s disease: preliminary findings. J Clin Pharmacol 1990; 30 (6): 556–61.CrossRefPubMed PFT�� clinical trial 18. Lynch G. Glutamate-based therapeutic approaches: ampakines. Curr Opin Pharmacol 2006; 6: 82–8.CrossRefPubMed 19. Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behaviour. Curr Drug Targets 2007; 8: 583–602.CrossRefPubMed
20. Deakin JFW, Slater P, Simpson MDC, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52: 1781–6.CrossRefPubMed 21. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990; 39: 25–32.CrossRefPubMed 22. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1155–8.CrossRefPubMed 23. Frye MA, Tsai GE, Huggins T, et al. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2006; 61: 162–6.CrossRefPubMed 24. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310–6.CrossRefPubMed 25. Lauterborn JC, Lynch G, Vanderklish P, et al. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000; 20 (1): 8–21.PubMed 26.